v3.26.3
SCHEDULE OF SEGMENT FINANCIAL INFORMATION BY BUSINESS SEGMENT (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Mar. 31, 2026
Segment Reporting [Line Items]          
Revenues $ 2,324 $ 1,818 $ 4,092 $ 3,578  
Cost of revenues (2,127) (2,116) (3,670) (3,720)  
Research and development (1,581) (2,450) (3,540) (5,536)  
Selling, general, and administrative (4,591) (4,913) (9,469) (9,600)  
Loss from operations (5,975) (7,661) (12,587) (15,278)  
Interest and finance expense (1,504) (639) (2,996) (1,187)  
Net loss before income taxes (7,818) (7,940) (15,753) (15,631)  
Depreciation and amortization 800 800 1,500 1,500  
Stock-based compensation expense 426 1,775 1,462 3,352  
Cash used in operations     (10,514) (8,979)  
Cash provided by investing     (1,648) 816  
Cash provided by financing     12,747 12,984  
Impact of exchange rates (41) 18 (62) 145  
Net change for the period     523 4,966  
Cash, cash equivalents and marketable securities 18,537   18,537   $ 17,263
TOTAL ASSETS 36,255   36,255   35,385
Total liabilities (30,131)   (30,131)   (29,175)
Non-controlling interest 797   797   84
Business Segment [Member] | Variable Interest Entities [Member] | Parent Company [Member]          
Segment Reporting [Line Items]          
Capital expenditures 751 246 959 445  
Revenues 2,324 1,818 4,092 3,578  
Cost of revenues 2,127 2,116 3,670 3,720  
Research and development 1,581 2,450 3,540 5,536  
Selling, general, and administrative 4,591 4,913 9,469 9,600  
Loss from operations (5,975) (7,661) (12,587) (15,278)  
Interest and finance expense (1,504) (639) (2,996) (1,187)  
Other non-operating income/(expense) (696) 42 (746) 129  
Net loss before income taxes (8,175) (8,258) (16,329) (16,336)  
Depreciation and amortization 847 820 1,644 1,625  
Stock-based compensation expense 426 1,775 1,462 3,352  
Cash used in operations (5,568) (4,453) (10,514) (8,979)  
Cash provided by investing (2,109) 240 (1,648) 816  
Cash provided by financing 9,689 8,918 12,747 12,984  
Impact of exchange rates (41) 18 (62) 145  
Net change for the period 1,971 4,723 523 4,966  
Cash, cash equivalents and marketable securities 13,705   13,705   11,641
All other assets 22,550   22,550   23,744
TOTAL ASSETS 36,255   36,255   35,385
Total liabilities (30,131)   (30,131)   (29,175)
Net assets 6,124   6,124   6,210
Non-controlling interest 797   797   84
Beyond Air [Member] | Business Segment [Member] | Variable Interest Entities [Member]          
Segment Reporting [Line Items]          
Capital expenditures 751 246 957 445  
Revenues 2,324 1,818 4,092 3,578  
Cost of revenues 2,127 2,116 3,670 3,720  
Research and development 1,262 1,696 3,009 3,930  
Selling, general, and administrative 3,509 3,734 7,172 7,062  
Loss from operations (4,574) (5,728) (9,759) (11,134)  
Interest and finance expense (1,504) (639) (2,996) (1,187)  
Other non-operating income/(expense) (785) 24 (886) 134  
Net loss before income taxes (6,863) (6,343) (13,641) (12,187)  
Depreciation and amortization 845 810 1,640 1,605  
Stock-based compensation expense 349 1,174 681 2,175  
Cash used in operations (4,145) (3,473) (8,500) (7,228)  
Cash provided by investing (2,190) (246) (1,863) (31)  
Cash provided by financing 8,936 8,418 8,766 12,484  
Impact of exchange rates 28 11 18 159  
Net change for the period 2,629 4,710 (1,579) 5,384  
Cash, cash equivalents and marketable securities 10,323   10,323   10,140
All other assets 22,471   22,471   23,901
TOTAL ASSETS 32,794   32,794   34,041
Total liabilities (29,057)   (29,057)   (28,224)
Net assets 3,737   3,737   5,817
Non-controlling interest    
Beyond Cancer Ltd [Member] | Business Segment [Member] | Variable Interest Entities [Member]          
Segment Reporting [Line Items]          
Capital expenditures  
Revenues  
Cost of revenues  
Research and development 41 379 95 908  
Selling, general, and administrative 169 760 358 1,712  
Loss from operations (210) (1,139) (453) (2,620)  
Interest and finance expense  
Other non-operating income/(expense) 18 13 59 (12)  
Net loss before income taxes (192) (1,126) (394) (2,632)  
Depreciation and amortization 1 10 3 20  
Stock-based compensation expense 65 521 131 1,033  
Cash used in operations (85) (273) (254) (712)  
Cash provided by investing 81 486 217 847  
Cash provided by financing  
Impact of exchange rates 3 (60) 34  
Net change for the period (4) 216 (97) 169  
Cash, cash equivalents and marketable securities 726   726   1,043
All other assets (289)   (289)   (219)
TOTAL ASSETS 437   437   824
Total liabilities (315)   (315)   (378)
Net assets 122   122   446
Non-controlling interest 9   9   64
NeuroNOS Ltd [Member] | Business Segment [Member] | Variable Interest Entities [Member]          
Segment Reporting [Line Items]          
Capital expenditures 2  
Revenues  
Cost of revenues  
Research and development 278 375 436 698  
Selling, general, and administrative 913 419 1,939 826  
Loss from operations (1,191) (794) (2,375) (1,524)  
Interest and finance expense  
Other non-operating income/(expense) 71 5 81 7  
Net loss before income taxes (1,120) (789) (2,294) (1,517)  
Depreciation and amortization 1 1  
Stock-based compensation expense 12 80 650 144  
Cash used in operations (1,338) (707) (1,760) (1,039)  
Cash provided by investing (2)  
Cash provided by financing 753 500 3,981 500  
Impact of exchange rates (69) 4 (20) (48)  
Net change for the period (654) $ (203) 2,199 $ (587)  
Cash, cash equivalents and marketable securities 2,656   2,656   458
All other assets 368   368   62
TOTAL ASSETS 3,024   3,024   520
Total liabilities (759)   (759)   (573)
Net assets 2,265   2,265   (53)
Non-controlling interest $ 788   $ 788   $ 20